Ankasa is powering tissue regeneration for an aging population.
Area of focus: Therapeutics Commencement date: August 15, 2015 Location: JLABS @ SSF
Broadly, Ankasa Regenerative Therapeutics is working on addressing tissue regeneration. Near-term the company is focusing on bone regeneration in the elderly.
The world’s population is aging. As we grow older, healing capacity inevitably deteriorates. Ankasa’s solution centers on a recombinant protein technology that activates the body’s own stem cells, restoring to geriatric tissues the healing capacity we experienced in youth. Ankasa has achieved production of these therapeutic proteins under manufacturing conditions and coupled this technology with proprietary formulations that significantly extend their therapeutic half-life. Applying these technologies in the laboratory setting has generated proof-of-concept data in multiple animal models of bone repair, segmental defect, osseointegration, and spinal fusion.
At Ankasa, our ambition is to amplify the body’s natural repair mechanisms and restore quality of life to older patients.